Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.

@article{Eerdekens2004PharmacokineticsAT,
  title={Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.},
  author={Mari{\"e}lle Eerdekens and Ilse van Hove and Bart M M Remmerie and Erik J L Mannaert},
  journal={Schizophrenia research},
  year={2004},
  volume={70 1},
  pages={91-100}
}
The pharmacokinetics and tolerability of long-acting risperidone (Risperdal Consta) were evaluated in a multicenter, prospective, open-label, 15-week study of 86 patients with schizophrenia. Subjects stabilized on 2, 4 or 6 mg of oral risperidone once daily for at least 4 weeks were assigned to receive i.m. injections of 25, 50 or 75 mg of risperidone, respectively, every 2 weeks for 10 weeks. The 90% confidence intervals for the i.m./oral ratios of the mean steady-state plasma-AUC, corrected… CONTINUE READING

From This Paper

Topics from this paper.
43 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Similar Papers

Loading similar papers…